NasdaqGM - Nasdaq Real Time Price • USD
Avadel Pharmaceuticals plc (AVDL)
As of 3:55 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 7 |
| Avg. Estimate | -0.21 | -0.12 | -0.4 | 1.03 |
| Low Estimate | -0.31 | -0.17 | -1.02 | 0.34 |
| High Estimate | -0.02 | -0.02 | -0.05 | 2.45 |
| Year Ago EPS | -0.48 | -0.83 | -2 | -0.4 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 7 |
| Avg. Estimate | 26.39M | 36.61M | 162.23M | 293.04M |
| Low Estimate | 23.01M | 33.5M | 146.5M | 248M |
| High Estimate | 33.38M | 43.62M | 176.8M | 334.2M |
| Year Ago Sales | -- | 630k | 27.96M | 162.23M |
| Sales Growth (year/est) | -- | 5,711.10% | 480.20% | 80.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.38 | -0.38 | -0.37 | -0.26 |
| EPS Actual | -0.48 | -0.83 | -0.41 | -0.29 |
| Difference | -0.1 | -0.45 | -0.04 | -0.03 |
| Surprise % | -26.30% | -118.40% | -10.80% | -11.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.21 | -0.12 | -0.4 | 1.03 |
| 7 Days Ago | -0.21 | -0.12 | -0.4 | 1.02 |
| 30 Days Ago | -0.21 | -0.12 | -0.4 | 1.02 |
| 60 Days Ago | -0.25 | -0.15 | -0.45 | 0.82 |
| 90 Days Ago | -0.25 | -0.15 | -0.44 | 0.8 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AVDL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 56.30% | -- | -- | 6.50% |
| Next Qtr. | 85.50% | -- | -- | 12.00% |
| Current Year | 80.00% | -- | -- | 5.30% |
| Next Year | 357.50% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/9/2024 |
| Maintains | Craig-Hallum: Buy to Buy | 3/5/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/5/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/5/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/5/2024 |
| Maintains | Needham: Buy to Buy | 3/5/2024 |
Related Tickers
DCPH Deciphera Pharmaceuticals, Inc.
14.72
+3.81%
EOLS Evolus, Inc.
11.52
+0.52%
ESPR Esperion Therapeutics, Inc.
1.9099
-4.04%
DVAX Dynavax Technologies Corporation
11.20
+0.27%
ELAN Elanco Animal Health Incorporated
13.28
+1.80%
ITCI Intra-Cellular Therapies, Inc.
73.06
+1.29%
NBIX Neurocrine Biosciences, Inc.
135.84
-1.39%
AMRX Amneal Pharmaceuticals, Inc.
5.87
-0.59%
AQST Aquestive Therapeutics, Inc.
4.0750
+3.69%
VTRS Viatris Inc.
11.60
+1.09%